Chemistry:Moguisteine
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H21NO5S |
| Molar mass | 339.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Moguisteine is a non-narcotic, peripherally acting antitussive.[1] In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo.[2] It has also been studied in small trials in comparison to codeine[3] and dextromethorphan,[4] and has similar efficacy to both. It has not been approved for use in the United States.[5]
It was discovered by searching for expectorants of the thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class.[6] Its mechanism of action may be the activation of ATP-sensitive potassium channels.[7]
References
- ↑ "Moguisteine: a novel peripheral non-narcotic antitussive drug". British Journal of Pharmacology 112 (3): 795–800. July 1994. doi:10.1111/j.1476-5381.1994.tb13149.x. PMID 7921605.
- ↑ "Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases". Drugs Under Experimental and Clinical Research 19 (6): 273–9. 1993. PMID 8013271.
- ↑ "The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough". Monaldi Archives for Chest Disease = Archivio Monaldi per le Malattie del Torace 50 (2): 93–7. April 1995. PMID 7613554.
- ↑ "Efficacy and Safety of Moguisteine in Comparison with Dextromethorphan in Patients with Persistent Cough". Drug Investigation 7 (2): 93–100. 1994. doi:10.1007/BF03257404.
- ↑ "Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines". Chest 129 (1 Suppl): 238S–249S. January 2006. doi:10.1378/chest.129.1_suppl.238S. PMID 16428717.
- ↑ "N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate". Journal of Medicinal Chemistry 38 (3): 508–25. February 1995. doi:10.1021/jm00003a014. PMID 7853344.
- ↑ "Involvement of ATP-sensitive K(+) channels in the anti-tussive effect of moguisteine". European Journal of Pharmacology 395 (2): 161–4. April 2000. doi:10.1016/s0014-2999(00)00197-7. PMID 10794823.
 |  |
